0 items USD 0.00Search
Your search for "CDK 4" gave back 99 results.
Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent...
Catalog:
MRRPB5
April 2023
Price: USD 2,900.00
Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
As the global economy recovers in 2021 and the supply of the industrial chain improves, the Cell Cycle Inhibitors market will undergo major changes...
Catalog:
Arsta
July 2022
Price: USD 3,360.00
As the global economy recovers in 2021 and the supply of the industrial chain improves, the Cell Cycle Inhibitors market will undergo major changes...
Catalog:
Arsta
March 2022
Price: USD 3,360.00
As the global economy recovers in 2021 and the supply of the industrial chain improves, the Cell Cycle Inhibitors market will undergo major changes...
Catalog:
Arsta
January 2022
Price: USD 3,360.00
Palbociclib is a drug manufactured by Pfizer, marketed under the brand Ibrance, and it is used for the treatment of hormone receptor-positive (HR+ve...
Catalog:
LPI
March 2023
Price: USD 3,660.00
Palbociclib is a drug manufactured by Pfizer, marketed under the brand Ibrance, and it is used for the treatment of hormone receptor-positive (HR+ve...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
Palbociclib is a drug manufactured by Pfizer, marketed under the brand Ibrance, and it is used for the treatment of hormone receptor-positive (HR+ve...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
HR+/HER2-Breast Cancer The “HR+HER2- Breast Cancer Industry Forecast” looks at past sales and reviews total world HR+HER2- Breast Cancer sales in...
Catalog:
LPI
March 2023
Price: USD 3,660.00
Palbociclib is a drug manufactured by Pfizer, marketed under the brand Ibrance, and it is used for the treatment of hormone receptor-positive (HR+ve...
Catalog:
MRRPB5
July 2023
Price: USD 4,900.00
HR+/HER2-Breast Cancer Highlights The global HR+HER2- Breast Cancer market was valued at US$ million in 2022 and is anticipated to reach US$ million...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
The “Non-Tyrosine Kinase Inhibitors Industry Forecast” looks at past sales and reviews total world Non-Tyrosine Kinase Inhibitors sales in 2022,...
Catalog:
LPI
March 2023
Price: USD 3,660.00
The global Non-Tyrosine Kinase Inhibitors market size was valued at US$ million in 2023. With growing demand in downstream market, the Non-Tyrosine...
Catalog:
LPI
February 2024
Price: USD 3,660.00
The global Non-Tyrosine Kinase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
HR+/HER2-Breast Cancer Market Analysis and Insights: Global HR+HER2- Breast Cancer Market The global HR+HER2- Breast Cancer market is projected to...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
